Vince & Associates Clinical Research Completes Enrollment Of Human Abuse Liability Study For Centanafadine For Adult ADHD

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Vince & Associates Clinical Research, a premier provider of early phase clinical research services, announced the completion of enrollment of a human abuse liability (HAL) clinical trial of centranafadine (formerly EB-1020). Centranafadine is a novel non-stimulant being developed by Neurovance of Cambridge, MA for the treatment of adult attention deficit hyperactivity disorder (ADHD).

Dr. Brad Vince, CEO and Medical Director of Vince & Associates Clinical Research expressed, “We are excited to be working with Neurovance on this important human abuse liability trial.”

Help employers find you! Check out all the jobs and post your resume.